recoveri
viru
nasopharyng
aspir
nasal
wash
bronchoalveolar
lavag
superior
nasopharyng
throat
swab
expector
sputum
latter
gener
contain
less
columnar
squamou
epitheli
cell
swab
contain
viral
transport
media
readili
avail
commerci
specimen
requir
antigen
nucleic
acid
test
similar
viru
isol
earli
experi
human
infect
suggest
viru
readili
detect
lower
respiratori
tract
sampl
upper
respiratori
tract
sampl
easier
collect
rate
load
detect
rna
higher
sampl
collect
pharynx
trachea
nose
viru
detect
serum
faec
cerebrospin
fluid
reflect
system
natur
infect
viraemia
associ
increas
mortal
serum
specimen
serolog
collect
acut
phase
within
day
symptom
onset
convalesc
phase
day
symptom
onset
test
parallel
tradit
method
influenza
viru
recoveri
clinic
specimen
cell
cultur
howev
rel
slow
time
time
receipt
specimen
laboratori
result
avail
clinician
least
day
led
use
rapid
assay
nucleic
acid
test
immunofluores
fewer
laboratori
isol
viru
nevertheless
viru
isol
usual
sensit
rapid
cultur
antigen
detect
assay
recov
novel
highli
diverg
strain
miss
test
provid
isol
subsequ
characteris
consider
potenti
vaccin
strain
allow
simultan
recoveri
respiratori
virus
appropri
rang
cell
line
use
influenza
viru
replic
within
cell
cultur
often
use
madin
darbi
canin
kidney
cell
detect
observ
cytopath
effect
gener
manifest
day
rapid
cultur
techniqu
detect
influenza
viru
replic
use
label
monoclon
antibodi
within
day
develop
cytopath
effect
sensit
compar
convent
cell
cultur
viru
readili
isol
facil
recommend
nose
throat
human
infect
well
blood
rectal
swab
viru
isol
allanto
amniot
caviti
embryon
chicken
egg
labour
intens
commonli
perform
diagnost
laboratori
howev
yield
higher
viral
titr
remain
vital
vaccin
product
initi
type
influenza
viru
isol
rapidli
conveni
accomplish
immunofluores
use
commerci
avail
monoclon
antibodi
perform
soon
possibl
isol
refer
viru
subtyp
method
haemagglutin
inhibit
assay
use
specif
antisera
techniqu
characteris
antigen
drift
shift
rapid
subtyp
techniqu
use
monoclon
antibodi
differenti
influenza
b
viru
subtyp
develop
use
viru
isol
rapid
cultur
assay
directli
clinic
specimen
subtyp
use
revers
transcript
polymeras
chain
reaction
primer
specif
variou
human
avian
influenza
strain
perform
viru
isol
directli
clinic
specimen
dna
microarray
use
detect
amplif
sequenc
sequenc
amplifi
haemagglutinin
neuraminidas
gene
import
subtyp
method
allow
rapid
identif
novel
highli
diverg
strain
analysi
strain
variat
determin
origin
outbreak
rapid
sequenc
avian
human
strain
use
monitor
evolut
virus
around
world
allow
understand
spread
drug
resist
like
candid
vaccin
strain
immunofluores
enzym
immunoassay
use
commerci
monoclon
antibodi
direct
conserv
influenza
antigen
common
rapid
assay
perform
directli
clinic
specimen
box
although
start
replac
nucleic
acid
test
indirect
direct
immunofluores
sensit
compar
cell
cultur
specimen
examin
fluoresc
microscop
assess
specimen
qualiti
made
report
clinician
columnar
epitheli
cell
seen
sensit
immunofluores
low
repeat
specimen
collect
request
monoclon
antibodi
common
respiratori
pathogen
parainfluenza
virus
type
adenoviru
respiratori
syncyti
viru
appli
specimen
immunofluores
reagent
yet
routin
avail
avail
neuraminidas
inhibitor
ad
impetu
develop
simpl
rapid
antigen
detect
assay
sometim
call
test
typic
test
produc
visual
result
immunochromatograph
strip
use
influenza
b
monoclon
antibodi
within
minut
ad
extract
specimen
box
evalu
assay
infect
limit
b
viru
infect
sensit
specif
compar
cell
cultur
immunofluores
sensit
compar
techniqu
specimen
qualiti
major
determin
perform
ideal
use
rapid
antigen
test
specimen
cell
cultur
immunofluores
nucleic
acid
test
submit
parallel
improv
sensit
obtain
viral
isol
type
vaccin
analysi
although
strategi
increas
cost
rapid
antigen
test
attract
virolog
laboratori
support
limit
remot
clinic
servic
laboratori
may
overwhelm
exampl
height
season
outbreak
pandem
may
also
role
doctor
surgeri
emerg
depart
fever
clinic
guid
earli
use
neuraminidas
inhibitor
individu
outbreak
close
environ
pandem
also
use
surveil
program
influenza
viru
rna
may
detect
clinic
specimen
nucleic
acid
test
techniqu
varieti
nucleic
acid
test
assay
use
primer
specif
rang
influenza
viru
gene
variou
extract
amplif
product
detect
method
describ
depend
primer
select
assay
may
primer
target
nucleoprotein
matrix
gene
sequenc
popular
detect
influenza
subtyp
although
studi
document
similar
sensit
nucleic
acid
test
cell
cultur
other
report
influenza
viru
detect
use
specimen
qualiti
time
transport
condit
may
less
critic
nucleic
acid
test
cultur
antigen
detect
viabl
viru
intact
infect
cell
need
preserv
influenza
viru
rna
detect
sever
day
longer
clinic
cours
cultiv
viru
potenti
allow
diagnosi
made
patient
specimen
qualiti
limit
surveil
program
involv
postal
submiss
specimen
yield
significantli
higher
cell
cultur
nucleic
acid
test
use
primer
sensit
assay
diagnosi
human
infect
although
turnaround
time
nucleic
acid
test
intermedi
cell
cultur
direct
antigen
detect
newer
techniqu
reduc
hour
less
multiplex
assay
develop
simultan
detect
influenza
viral
bacteri
respiratori
pathogen
directli
clinic
specimen
quantifi
viral
load
clinic
specimen
done
human
patient
assess
prognosi
measur
antivir
efficaci
nucleic
acid
test
subtyp
influenza
virus
use
primer
analys
strain
variat
genet
sequenc
thu
complement
tradit
role
antigen
characteris
viral
isol
serolog
use
specimen
viru
isol
antigen
detect
neg
inadequ
unavail
also
provid
use
delay
surveil
data
serolog
diagnosi
influenza
retrospect
requir
acut
convalesc
serum
sampl
furthermor
gener
provid
inform
antigen
composit
circul
strain
influenza
viru
infect
gener
repres
reinfect
peopl
immun
thu
detect
igg
total
antibodi
singl
serum
specimen
diagnost
recent
infect
definit
serolog
diagnosi
acut
influenza
requir
demonstr
increas
antibodi
titr
pair
acut
convalesc
serum
sampl
unfortun
acut
specimen
frequent
collect
howev
singl
high
antibodi
titr
context
compat
clinic
ill
period
circul
influenza
activ
provid
presumpt
evid
recent
infect
varieti
assay
avail
includ
complement
fixat
haemagglutin
inhibit
assay
singl
radial
haemolysi
neutralis
immunofluoresc
enzym
immunoassay
tradit
gold
standard
techniqu
detect
antibodi
neutralis
haemagglutin
inhibit
assay
differenti
includ
serolog
respons
antibodi
level
correl
accur
protect
suscept
influenza
vaccin
respons
complement
fixat
commonli
use
easier
perform
haemagglutin
inhibit
assay
neutralis
distinguish
subtyp
recent
influenza
infect
suggest
fourfold
rise
complement
fixat
titr
singl
high
titr
two
class
drug
effect
influenza
viru
infect
adamantan
channel
inhibitor
amantadin
rimantadin
neuraminidas
inhibitor
zanamivir
oseltamivir
amantadin
resist
emerg
within
day
treatment
onset
patient
mediat
amino
acid
substitut
transmembran
region
adamantan
resist
increas
around
world
neuraminidas
inhibitor
resist
commonli
associ
varieti
amino
acid
substitut
conserv
residu
neuraminidas
enzym
activ
site
date
howev
virus
mutat
shown
impair
replic
cell
cultur
anim
model
mutat
haemagglutinin
site
occur
lead
reduc
viral
depend
neuraminidas
function
resist
neuraminidas
inhibitor
rare
seen
immunocompet
human
clinic
trial
although
recent
report
children
infect
influenza
japan
vietnames
human
patient
treat
neuraminidas
inhibitor
show
resist
may
common
initi
suppos
resist
mutat
detect
treatment
immunocompromis
individu
situat
requir
studi
drug
resist
test
use
genotyp
sequenc
analys
neuraminidas
gene
phenotyp
assay
assay
routin
avail
therapeut
failur
surveil
purpos
isol
refer
appropri
refer
laboratori
newer
molecular
method
allow
rapid
resist
determin
clinic
relev
time
frame
pandem
neuraminidas
inhibitor
may
use
extens
develop
variou
laboratori
techniqu
avail
detect
influenza
virus
whether
current
human
strain
novel
pandem
strain
pandem
level
laboratori
servic
vari
centr
specialist
virolog
laboratori
undertak
full
rang
influenza
viru
test
includ
nucleic
acid
test
rapid
antigen
detect
cultur
type
isol
potenti
use
vaccin
detect
antivir
drug
resist
laboratori
may
follow
limit
strategi
depend
locat
eg
rural
area
popul
eg
public
privat
hospit
access
specialis
laboratori
challeng
laboratori
ensur
assay
accur
virus
current
strain
yet
circul
australia
genet
variat
may
particularli
affect
nucleic
acid
test
lack
clinic
sampl
australia
individu
make
assess
variou
method
uncertain
recent
urgent
fund
nation
health
medic
research
council
nhmrc
allow
assess
qualiti
assur
variou
assay
anoth
major
challeng
determin
diagnost
differ
pandem
phase
vari
laboratori
depend
virolog
expertis
capac
patient
popul
avail
variou
assay
stage
pandem
earli
phase
contain
paramount
highli
sensit
test
pandem
nucleic
acid
test
requir
test
rapid
identifi
first
arriv
cluster
diseas
allow
earli
antivir
treatment
prophylaxi
infect
control
caus
respiratori
infect
need
exclud
earli
identif
requir
cooper
commun
public
health
offic
treat
clinician
public
privat
laboratori
pandem
becom
widespread
australia
test
strategi
may
chang
one
could
argu
clinic
identif
suffic
laboratori
test
limit
patient
requir
hospit
admiss
particular
outbreak
influenza
assay
immunofluoresc
immunochromatograph
rapid
antigen
test
may
use
identifi
influenza
infect
pandem
stage
antivir
resist
test
yet
routin
avail
australia
import
antivir
drug
use
extens
pandem
project
partial
support
nhmrc
grant
imag
box
provid
david
adam
ken
mcphie
centr
infecti
diseas
microbiolog
laboratori
servic
institut
clinic
patholog
medic
research
westmead
hospit
laboratori
undertaken
clinic
research
project
fund
laboratori
suppli
compani
relat
laboratori
techniqu
discuss
paper
roch
product
pti
ltd
paid
travel
expens
domin
dwyer
david
smith
attend
lancet
pandem
influenza
meet
singapor
april
